Charles River works on rare disease gene therapy; Emergent gets $75M for anthrax vaccine; EuroAPI hires new COO 

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

Charles Riv­er and the Aus­tralian non­prof­it Ge­net­ic Cures for Kids part­nered on Tues­day to de­vel­op and man­u­fac­ture a gene ther­a­py for the hered­i­tary neu­rode­gen­er­a­tive dis­ease called spas­tic para­ple­gia type 56 (SPG56) by us­ing Charles Riv­er’s plas­mid pro­duc­tion plat­form eX­pDNA. SPG56 is a rare dis­ease af­fect­ing chil­dren, leav­ing them un­able to walk and talk in­de­pen­dent­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.